申请人:Centro Nacional de Investigaciones Oncológicas
(CNIO)
公开号:EP2524918A1
公开(公告)日:2012-11-21
There is provided compounds of formula I,
wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a , B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) and, additionally, HDAC, is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
提供了I式化合物,其中A1、A4、A4a、A5、B1、B1a、B2、B2a、B3、B3a、B4、B4a和R3的含义在说明中给出,并且其药学上可接受的酯、酰胺、溶剂合物或盐,这些化合物在治疗需要或期望抑制蛋白质或脂质激酶(例如PI3-K和/或mTOR)以及额外的HDAC的疾病中有用,特别是在治疗癌症或增生性疾病方面。